表紙
市場調査レポート

世界のHIV/AIDS治療薬市場:一定容量・1日1回の併用薬物の普及による成長促進

HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth

発行 GBI Research 商品コード 216701
出版日 ページ情報 英文 111 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
世界のHIV/AIDS治療薬市場:一定容量・1日1回の併用薬物の普及による成長促進 HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth
出版日: 2012年11月09日 ページ情報: 英文 111 Pages
概要

世界の主要7カ国のHIV/AIDS治療薬の市場規模は、2011年には135億米ドル、2018年には218億米ドルに達すると予測されています。また年平均(CAGR)成長率は2004〜2011年は12.5%、2011〜2018年は7%と推計されています。マルチクラスの配合剤(Atripla、Compleraなど)の一回投与が普及したことが、市場の成長を促進しています。

当レポートでは、世界のHIV/AIDS治療薬市場について調査し、市場の特性、世界市場の全体的な構造・動向、収益分析と予測(過去8年間の実績値と今後7年間の予測値)、主要国市場の詳細動向、パイプライン評価、参入企業の競合プロファイル、主な資本取引の動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 世界のHIV/AIDS治療薬市場:イントロダクション

第3章 世界市場の概要

  • 疾患概要
  • HIV/AIDS治療に関するWHOのガイドライン
  • HIV/AIDS治療に利用されている薬剤クラス
    • ヌクレオシド/ヌクレオチド逆転写酵素阻害剤(NRTI)
    • 非ヌクレオシド逆転写酵素阻害剤(NRTI)
    • プロテアーゼ阻害剤
    • ウイルス融合阻害剤
    • CCR5補助受容体拮抗薬
    • HIVインテグラーゼストランド転写阻害剤
    • マルチクラス併用製品
  • 主な市販製品
    • Atripla
    • Truvada
    • Reyataz
    • Sustiva
    • Isentress
  • HIV/AIDSワクチン研究に関する近年の成果

第4章 市場の特性と予測

  • イントロダクション
  • 市場予測
    • 薬剤のクラス別の市場背は
  • 市場シェア:ブランド薬とジェネリック薬
  • 企業別の市場シェア
  • 年間治療費
  • 治療使用形態
    • 罹患人口
    • 受診人口
    • 処方人口
  • 促進因子と阻害因子

第5章 米国

  • 市場概要
  • 市場収益の予測
  • 年間治療費
  • 治療使用形態

第6章 欧州主要5カ国

  • 市場概要
  • 市場収益の予測
  • 各国の市場収益
  • 年間治療費
  • 治療使用形態

第7章 日本

  • 市場概要
  • 市場収益の予測
  • 年間治療費
  • 治療使用形態

第8章 新興国市場

  • 中国
    • 疫学
    • 中国のHIV/AIDS政策展開上の重要な動き
    • 中国での治験状況
  • インド
    • 概要
    • 国家AIDS管理計画
    • 治療のガイドライン
    • TRIPS協定(知的所有権の貿易関連の側面に関する協定)とジェネリック医薬品に対する影響
    • HIV/AIDS治療市場の近年の動き
  • オーストラリア
    • 概要
    • 高度専門(Section 100)薬計画

第9章 パイプライン分析

  • 概要
  • 治験中の有望薬剤
    • Stribild (Quad)
    • Cobicistat
    • JTK-303
    • 1349572
    • 572-Trii

第10章 競合環境

  • イントロダクション
  • 主要企業プロファイル
    • Gilead Sciences, Inc
    • 10.2.2 GlaxoSmithKline (GSK)
    • BMS
    • Abbott Laboratories
    • Merck
    • Johnson & Johnson (J&J)
    • Roche

第11章 戦略的な業界再編

  • 年間の資本取引件数
  • 資本取引の種類別動向
  • 資本取引の地域別動向
  • 主な企業合併・買収(M&A)の概要(全2件)
  • 主なライセンス契約の概要(全2件)
  • 主なパートナーシップの概要(全3件)

第12章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC250MR

Summary

GBI Research, a leading business intelligence provider, has released its latest research, "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth". The report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV/AIDS therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the market for HIV/AIDS therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report provides branded and generics segmentation in the therapeutic landscape segment. In addition, it analyzes the HIV/AIDS therapeutics market in India, China and Australia. The report discusses the global pipeline for all the HIV/AIDS molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research found that the HIV/AIDS therapeutics market in the top seven markets was valued at $13.5 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 12.5% during the 2004-2011 historic period. The market is projected to witness growth of 7% during the 2011-2018 forecast period to reach $21.8 billion. The growth is primarily driven by the increase in the use of single dose multi-class combination drugs such as Atripla, Complera. With the recent launch of Stribild (previously known as Quad), the multi-class combination drugs would drive the market.

Scope

  • Annualized market data for the HIV/AIDS therapeutics market from 2004 to 2011, forecast forward to 2018.
  • Analysis of the HIV/AIDS therapeutics market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Analysis of the HIV/AIDS therapeutics market in India, China and Australia.
  • Market characterization of the HIV/AIDS therapeutics market including market size, annual cost of treatment, and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of pipeline molecules in various phases of drug development.
  • Competitive benchmarking of leading companies. Key companies studied in this report are Gilead Sciences, Bristol-Myers Squibb, GlaxoSmithKline, Abbott Laboratories, Johnson & Johnson, Merck, and Roche.
  • Key M&A activities and licensing agreements that have taken place between 2008 and up to June 2012 in the global HIV/AIDS therapeutics market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Executive Summary

Stribild Introduction to Reinforce HIV/AIDS Revenues as Key Patents Expire.

Gilead Science's combination drug Stribild (previously known as the "Quad pill") is expected to bolster the HIV/AIDS therapeutics market as a number of significant medications go off-patent over the next few years, states business intelligence provider GBI Research in its latest publication.

Forecasts from the firm's latest report indicate that the global HIV/AIDS therapeutics market will increase in value at a Compound Annual Growth Rate (CAGR) of 7% between the years 2011 and 2018, from $13.5 billion to $21.8 billion.

As a consequence of the on-going patent-cliff, this predicted growth rate is less than the market experienced in previous years. Between 2004 and 2011, the market experienced a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva and Reyataz (both produced by Bristol-Myers Squibb) in 2014 and 2017 respectively, a more modest increase is predicted.

However, the market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact.

Gilead announced Stribild's initial price as $28,500, which is one-third greater than that of Atripla, but with impressive efficacy and strong patient compliance, GBI Research do not expect this higher cost to be a significant barrier to widespread use.

HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth

This report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. HIV/AIDS Therapeutics Market to 2018 - Introduction

3. HIV/AIDS Therapeutics Market to 2018 - Overview

  • 3.1. Disease Overview
    • 3.1.1. Diagnostic Tests for HIV
  • 3.2. WHO Guidelines for HIV/AIDS Treatment
    • 3.2.1. WHO Clinical Staging of HIV Disease in Adults and Adolescents
    • 3.2.2. Summary of Changes to the WHO's Guidelines on Initiation of ART based on CD4 Count and Clinical Staging
    • 3.2.3. Summary of Changes to WHO's Guidelines on First-line Antiretrovirals
    • 3.2.4. Summary of Changes to the WHO's Guidelines on Second-line Antiretrovirals
  • 3.3. Drugs Classes Used in HIV/AIDS Treatment
    • 3.3.1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
    • 3.3.2. Non-nucleoside Reverse Transcriptase Inhibitors
    • 3.3.3. Protease Inhibitors
    • 3.3.4. Fusion Inhibitors
    • 3.3.5. CCR5 Co-receptor Antagonist
    • 3.3.6. Integrase Inhibitors
    • 3.3.7. Multi-class Combination Drugs
  • 3.4. Key Marketed Products
    • 3.4.1. Atripla
    • 3.4.2. Truvada
    • 3.4.3. Reyataz
    • 3.4.4. Sustiva
    • 3.4.5. Isentress
  • 3.5. Advancements in HIV/AIDS Vaccine Research

4. HIV/AIDS Therapeutics Market to 2018 - Market Characterization and Forecast

  • 4.1. Introduction
  • 4.2. Revenue Forecast
    • 4.2.1. Market Share by Drug Class (%), 2011
  • 4.3. Branded Versus Generics Market Share (%), 2011
  • 4.4. Market Share by Company (%), 2011
  • 4.5. Annual Cost of Therapy
  • 4.6. Treatment Usage Pattern
    • 4.6.1. Diseased Population
    • 4.6.2. Diagnosed Population
    • 4.6.3. Prescription Population
  • 4.7. HIV/AIDS Therapeutics Market - Drivers and Restraints
    • 4.7.1. HIV/AIDS Therapeutics Market - Drivers
    • 4.7.2. Market Restraints

5. HIV/AIDS Therapeutics Market to 2018 - The US

  • 5.1. Market Overview
  • 5.2. Revenue Forecast
  • 5.3. Annual Cost of Therapy
  • 5.4. Treatment Usage Pattern
    • 5.4.1. Diseased Population
    • 5.4.2. Diagnosed Population
    • 5.4.3. Prescription Population

6. HIV/AIDS Therapeutics Market to 2018 - Top Five European Countries

  • 6.1. Market Overview
  • 6.2. Revenue Forecast: Top Five European Countries
  • 6.3. Revenue by Geographical Segmentation
  • 6.4. Annual Cost of Therapy
  • 6.5. Treatment Usage Pattern
    • 6.5.1. Diseased Population
    • 6.5.2. Diagnosed Population
    • 6.5.3. Prescription Population

7. HIV/AIDS Therapeutics Market to 2018 - Japan

  • 7.1. Market Overview
  • 7.2. Revenue Forecast
  • 7.3. Annual Cost of Therapy
  • 7.4. Treatment Usage Pattern
    • 7.4.1. Diseased Population
    • 7.4.2. Diagnosed Population
    • 7.4.3. Prescription Population

8. HIV/AIDS Therapeutics Market to 2018 - Emerging Markets

  • 8.1. China
    • 8.1.1. Epidemiology
    • 8.1.2. Important Events in China's HIV/AIDS Policy Development
    • 8.1.3. Clinical Trials in China
  • 8.2. India
    • 8.2.1. Overview
    • 8.2.2. National AIDS Control Programs
    • 8.2.3. Treatment Guidelines
    • 8.2.4. Trade Related Aspects of Intellectual Property Rights Agreement and its Impact on Generics
    • 8.2.5. Recent Developments in HIV/AIDS Therapeutics Market in India
  • 8.3. Australia
    • 8.3.1. Overview
    • 8.3.2. Highly Specialized Drugs (Section 100) Program

9. HIV/AIDS Therapeutics Market to 2018 - Pipeline Analysis

  • 9.1. Overview
  • 9.2. Promising Molecules in Late Stages of Clinical Development
    • 9.2.1. Stribild (Quad)
    • 9.2.2. Cobicistat
    • 9.2.3. JTK-303
    • 9.2.4. 1349572
    • 9.2.5. 572-Trii

10. HIV/AIDS Therapeutics Market to 2018 - Competitive Landscape

  • 10.1. Introduction
  • 10.2. Major Company Profiles
    • 10.2.1. Gilead Sciences, Inc
    • 10.2.2. GlaxoSmithKline (GSK)
    • 10.2.3. BMS
    • 10.2.4. Abbott Laboratories
    • 10.2.5. Merck
    • 10.2.6. Johnson & Johnson (J&J)
    • 10.2.7. Roche

11. HIV/AIDS Therapeutics Market to 2018 - Strategic Consolidations

  • 11.1. Deals by Year
  • 11.2. Deals by Type
    • 11.2.1. Deals by Value
  • 11.3. Deals by Geography
  • 11.4. Summary of Major M&A Deals
    • 11.4.1. Daiichi Sankyo Acquires Majority Stake in Ranbaxy Labs
    • 11.4.2. Endo Pharma Acquires Indevus Pharma
  • 11.5. Summary of Major Licensing Deals
    • 11.5.1. GlaxoSmithKline Enters into Licensing Agreement with Idenix Pharma
    • 11.5.2. BMS Enters into Licensing Agreement with Oncolys BioPharma
  • 11.6. Summary of Major Partnerships
    • 11.6.1. GlaxoSmithKline Enters into an Agreement with Concert Pharma
    • 11.6.2. Chemrar Enters into Joint Venture Agreement with Rusnano
    • 11.6.3. GenVec Enters into an Agreement with SAIC-Frederick

12. HIV/AIDS Therapeutics Market to 2018 - Appendix

  • 12.1. Market Definitions
  • 12.2. Abbreviations
  • 12.3. Bibliography
  • 12.4. Research Methodology
    • 12.4.1. Coverage
    • 12.4.2. Secondary Research
    • 12.4.3. Primary Research
  • 12.5. Therapeutic Landscape
    • 12.5.1. Epidemiology-based Forecasting
    • 12.5.2. Market Size by Geography
  • 12.6. Geographical Landscape
  • 12.7. Pipeline Analysis
  • 12.8. Competitive Landscape
    • 12.8.1. Expert Panel Validation
  • 12.9. Contact Us
  • 12.10. Disclaimer

List of Tables

  • Table 1: HIV/AIDS Therapeutics Market to 2018, WHO Clinical Staging of HIV Disease in Adults and Adolescents, 2010
  • Table 2: HIV/AIDS Therapeutics Market to 2018, Summary of Changes to the WHO's Guidelines on Initiation of Antiretroviral Therapy Based on CD4 Count and Clinical Staging, 2010
  • Table 3: HIV/AIDS Therapeutics Market to 2018, Summary of Changes to WHO's Guidelines on First-line Antiretrovirals, 2010
  • Table 4: HIV/AIDS Therapeutics Market to 2018, Summary of Changes to WHO's Guidelines on Second-line Antiretrovirals, 2010
  • Table 5: HIV/AIDS Therapeutics Market to 2018, Nucleoside/Nucleotide Reverse Transcriptase Inhibitors, Global Sales ($m), 2011
  • Table 6: HIV/AIDS Therapeutics Market to 2018, Non-Nucleoside Reverse Transcriptase Inhibitors, Global Sales ($m), 2011
  • Table 7: HIV/AIDS Therapeutics Market to 2018, Protease Inhibitors, Global Sales ($m), 2011
  • Table 8: HIV/AIDS Therapeutics Market to 2018, Fusion Inhibitors, Global Sales ($m), 2011
  • Table 9: HIV/AIDS Therapeutics Market to 2018, CCR5 Co-receptor Antagonist Global Sales ($m), 2011
  • Table 10: HIV/AIDS Therapeutics Market to 2018, Integrase Inhibitors Global Sales ($m), 2011
  • Table 11: HIV/AIDS Therapeutics Market to 2018, Multi-class Combination Drugs, Global Sales ($m), 2011
  • Table 12: HIV/AIDS Therapeutics Market to 2018, Global, Market Share of Key Products (%), 2011
  • Table 13: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue ($bn), 2004-2011
  • Table 14: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2011-2018
  • Table 15: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011
  • Table 16: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2011-2018
  • Table 17: HIV/AIDS Therapeutics Market, Top Seven Markets, Treatment Usage Pattern ('000), 2004-2011
  • Table 18: HIV/AIDS Therapeutics Market, Top Seven Markets, Treatment Usage Pattern Forecast ('000), 2011-2018
  • Table 19: HIV/AIDS Therapeutics Market to 2018, The US, Patent Expiries, 2012-2018
  • Table 20: HIV/AIDS Therapeutics Market to 2018, The US, Revenue ($bn), 2004-2011
  • Table 21: HIV/AIDS Therapeutics Market to 2018, The US, Revenue Forecast ($bn), 2011-2018
  • Table 22: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy ($), 2004-2011
  • Table 23: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy Forecast ($), 2011-2018
  • Table 24: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern ('000), 2004-2011
  • Table 25: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern Forecast ('000), 2011-2018
  • Table 26: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue ($bn), 2004-2011
  • Table 27: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast ($bn), 2011-2018
  • Table 28: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue by Geographical Segmentation ($m), 2004-2011
  • Table 29: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast by Geographical Segmentation ($m), 2011-2018
  • Table 30: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011
  • Table 31: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2011-2018
  • Table 32: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment Usage Pattern ('000), 2004-2011
  • Table 33: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment Usage Pattern Forecast ('000), 2011-2018
  • Table 34: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue ($m), 2004-2011
  • Table 35: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue Forecast ($m), 2011-2018
  • Table 36: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy ($), 2004-2011
  • Table 37: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy Forecast ($), 2011-2018
  • Table 38: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern ('000), 2004-2011
  • Table 39: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern Forecast ('000), 2011-2018
  • Table 40: HIV/AIDS Therapeutics Market, China, Diseased Population ('000), 2005-2011
  • Table 41: HIV/AIDS Therapeutics Market, Pipeline Molecules, China, 2012
  • Table 42: HIV/AIDS Therapeutics Market to 2018, India, ART Centre Coverage and Patients on First-line Therapy, 2005-2010
  • Table 43: HIV/AIDS Therapeutics Market to 2018, India, HIV/AIDS Prevalence, 2004-2009
  • Table 44: HIV/AIDS Therapeutics Market to 2018, India, Treatment Guidelines, 2011
  • Table 45: HIV/AIDS Therapeutics Market to 2018, Australia, Number of HIV Cases and MSM (%), 2001-2010
  • Table 46: HIV/AIDS Therapeutics Market to 2018, Australia, List of Approved Medications Under Highly Specialized Drugs (Section 100) Program, 2012
  • Table 47: HIV/AIDS Therapeutics Market to 2018, Australia, Number of People Prescribed ART through the Highly Specialized Drugs (S100) Program, 2006-2010
  • Table 48: HIV Therapeutics Market, Global, Number of Molecules in Pipeline by Phase, 2012
  • Table 49: HIV Therapeutics Market, Global, Promising Molecules in Late Stages of Clinical Development, 2012
  • Table 50: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type, 2008-2012
  • Table 51: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Mergers and Acquisitions Deals, 2008-2012
  • Table 52: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Partnership Deals, 2008-2012
  • Table 53: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Partnership Deals, 2008-2012
  • Table 54: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Deals, 2008-2012
  • Table 55: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Deals, 2008-2012
  • Table 56: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Deals, 2008-2012
  • Table 57: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value ($m), 2008-2012
  • Table 58: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Geography, 2008-2012

List of Figures

  • Figure 1: HIV/AIDS Therapeutics Market to 2018, Global, Treatment Algorithm, 2012
  • Figure 2: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2004-2018
  • Figure 3: HIV/AIDS Therapeutics Market to 2018, Global, Market Share by Drug Class (%), 2011
  • Figure 4: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Branded Versus Generics Market Share (%), 2011
  • Figure 5: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Market Share by Company (%), 2011
  • Figure 6: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018
  • Figure 7: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Treatment Usage Pattern ('000), 2004-2018
  • Figure 8: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Drivers and Restraints, 2012
  • Figure 9: HIV/AIDS Therapeutics Market to 2018, The US, Revenue Forecast ($bn), 2004-2018
  • Figure 10: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy ($), 2004-2018
  • Figure 11: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern ('000), 2004-2018
  • Figure 12: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast ($bn), 2004-2018
  • Figure 13: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast by Geographical Segmentation ($m), 2004-2018
  • Figure 14: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2004-2018
  • Figure 15: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment Usage Pattern ('000), 2004-2018
  • Figure 16: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue Forecast ($m), 2004-2018
  • Figure 17: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy ($), 2004-2018
  • Figure 18: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern ('000), 2004-2018
  • Figure 19: HIV/AIDS Therapeutics Market, China, Diseased Population ('000), 2005-2011
  • Figure 20: HIV/AIDS Therapeutics Market, Important Events in China's HIV/AIDS Policy Development, 1985-2012
  • Figure 21: HIV/AIDS Therapeutics Market to 2018, India, ART Centre Coverage and Patients on First Line Therapy, 2005-2010
  • Figure 22: HIV/AIDS Therapeutics Market to 2018, India, HIV/AIDS Prevalence, 2004-2009
  • Figure 23: HIV/AIDS Therapeutics Market to 2018, Australia, Number of Diagnosed HIV Cases and MSM (%), 2001-2010
  • Figure 24: HIV/AIDS Therapeutics Market to 2018, Global, Pipeline by Phase (%), 2012
  • Figure 25: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Market Share by Company (%), 2011
  • Figure 26: HIV/AIDS Therapeutics Market to 2018, Gilead Sciences, SWOT Analysis, 2012
  • Figure 27: HIV/AIDS Therapeutics Market to 2018, GSK, SWOT Analysis, 2012
  • Figure 28: HIV/AIDS Therapeutics Market to 2018, BMS, SWOT Analysis, 2012
  • Figure 29: HIV/AIDS Therapeutics Market to 2018, Abbott, SWOT Analysis, 2012
  • Figure 30: HIV/AIDS Therapeutics Market to 2018, Merck, SWOT Analysis, 2012
  • Figure 31: HIV/AIDS Therapeutics Market to 2018, J&J, SWOT Analysis, 2012
  • Figure 32: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Year, 2008-2012
  • Figure 33: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type (%), 2008-2012
  • Figure 34: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value (%), 2008-2012
  • Figure 35: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Geography (%), 2008-2012
  • Figure 36: GBI Research Market Forecasting Model
Back to Top